# Novaliq

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novaliq

- Industry: Pharmaceuticals
- Headquarters: Heidelberg, Germany
- Website: www.novaliq.de
- Total disclosed funding: $18M
- Latest round: Series E (Mar 18, 2013)
- Investors on record: 1

## About

Novaliq GmbH is a biotechnology firm focused on developing innovative therapies for severe conditions, particularly in the ophthalmic and dermatological fields, utilizing proprietary technologies to enhance drug delivery and efficacy.Founded in 2007 in Heidelberg, Germany, Novaliq GmbH specializes in advanced drug delivery systems for ophthalmology and dermatology. The company has undergone strategic pivots, including its concentration on liquid formulations for local drug delivery, and has secured a total of USD 53 mn in funding through four deals, the latest being in October 2018 led by Dievini. The company is valued at approximately USD 142.99 mn as of its most recent funding round. The current CEOs are Christian Roesky and Frank Löscher.Novaliq GmbH primarily develops advanced therapeutic solutions for ophthalmic and dermatological applications. Their flagship product, utilizing proprietary delivery technology, aims to enhance bioavailability and effectiveness while minimizing side effects. The focus lies in treating conditions such as dry eye disease and localized skin ailments, with ongoing clinical trials to validate their innovative formulations.For the most recent fiscal year ending in 2022, Novaliq GmbH reported a revenue of USD 7.81 mn and an EBITDA of USD -7.84 mn, indicating significant investment in product development and clinical trials.Novaliq GmbH plans to leverage its recent funding of USD 53 mn from October 2018 to advance its clinical trial programs and to support the commercialization of its innovative product pipeline. The company aims to launch new therapeutic options in ophthalmology and dermatology, targeting expansion into additional European and North American markets by 2025. The funding is crucial for expediting the development and regulatory processes necessary for their upcoming product launches.

## Funding rounds

- Series E, Mar 18, 2013, $18M — Dievini

## Investors

- Dievini (https://capitalatlas.ai/funds/dievini) — Series E